53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
Hyfe pilot study tests a digital therapeutic combining passive cough monitoring with behavioral suppression techniques delivered through the CoughPro app.
This narrative review by Hyfe's R&D team makes the case that continuous cough monitoring (CCM), powered by acoustic AI, transforms cough from a subjective symptom into a quantifiable digital biomarker.
Independent ERS 2025 NeuroCOUGH trial uses the Hyfe Cough Tracker to test feasibility of studying azithromycin's effect on cough and oesophageal motility.
Independent ERS 2025 trial uses the Hyfe Cough Tracker to show azithromycin reduces objective cough frequency by week one in chronic respiratory disease.
Cough is a ubiquitous health indicator whose global physical, psychological, and financial burden is extremeand underappreciated. As a disruptive, discrete, and information-rich symptom that is associated with a myriadof diseases, cough is also the ideal clinical endpoint. And yet, even in the age of mobile health, AI, and BigData, cough continues to be assessed mainly through subjective surveys and brief acoustic recordings withbulky and expensive clinical devices. Half the world population now carries smartphones that, when combinedwith AI-powered software, can be used as clinical tools for quantifying cough endpoints objectively.
Scalable mobile cough monitoring has the potential to transform clinical trials by increasing their success rate, decimatingtheir costs, accelerating products to market, and improving health equity worldwide.
